Page last updated: 2024-09-04

febuxostat and mk 0663

febuxostat has been researched along with mk 0663 in 2 studies

Compound Research Comparison

Studies (febuxostat)	Trials (febuxostat)	Recent Studies (post-2010) (febuxostat)	Studies (mk 0663)	Trials (mk 0663)	Recent Studies (post-2010) (mk 0663)
818	133	710	549	173	265

Protein Interaction Comparison

Protein	Taxonomy	mk 0663 (IC50)
Prostaglandin G/H synthase 2	Homo sapiens (human)	0.4586
Prostaglandin G/H synthase 2	Ovis aries (sheep)	0.23
Mitogen-activated protein kinase 14	Homo sapiens (human)	0.53

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ	1
Hu, SX; Lei, XM; Shen, GF; Ye, C; Yu, F; Yu, YK; Zhang, ST	1

Trials

1 trial(s) available for febuxostat and mk 0663

Article	Year
Combination Therapies of Diacerein and Febuxostat Inhibit IL-1β Responses and Improve Clinical Symptoms in Patients With Refractory Gout. American journal of therapeutics, 2017, Volume: 24, Issue:3 Topics: Adult; Anthraquinones; Anti-Inflammatory Agents; C-Reactive Protein; Case-Control Studies; Drug Therapy, Combination; Etoricoxib; Febuxostat; Female; Follow-Up Studies; Gout; Gout Suppressants; Humans; Interleukin-18; Interleukin-1beta; Male; Middle Aged; Prospective Studies; Pyridines; Sulfones; Treatment Outcome; Uric Acid	2017

Article

Year

Combination Therapies of Diacerein and Febuxostat Inhibit IL-1β Responses and Improve Clinical Symptoms in Patients With Refractory Gout.

American journal of therapeutics, 2017, Volume: 24, Issue:3

Topics: Adult; Anthraquinones; Anti-Inflammatory Agents; C-Reactive Protein; Case-Control Studies; Drug Therapy, Combination; Etoricoxib; Febuxostat; Female; Follow-Up Studies; Gout; Gout Suppressants; Humans; Interleukin-18; Interleukin-1beta; Male; Middle Aged; Prospective Studies; Pyridines; Sulfones; Treatment Outcome; Uric Acid

2017

Other Studies

1 other study(ies) available for febuxostat and mk 0663

Article	Year
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. Toxicological sciences : an official journal of the Society of Toxicology, 2013, Volume: 136, Issue:1 Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests	2013

Article

Year

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.

Toxicological sciences : an official journal of the Society of Toxicology, 2013, Volume: 136, Issue:1

Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests

2013